Structure Therapeutics 주식 (NASDAQ: GPCR)

에 대한 최신 뉴스 Structure Therapeutics (NASDAQ:GPCR) 주식

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Biotech

Equities

News

Health Care

Global

Markets

BHVN

GPCR

RHHBY

스트럭처 테라퓨틱스(NASDAQ:GPCR)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다. What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#34;비중확대(Overweight)&#34; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.

스트럭처 테라퓨틱스 주식은 비만 치료제 시장의 돌파구로 80% 상승 예상: JP모건

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

Anatoly Yakovenko, the co-founder of the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ecosystem, argued against a federal government-controlled cryptocurrency reserve Wednesday, citing a threat to decentralization.
What Happened: In an X post, Yakovenko outlined his order of preference for a potential cryptocurrency reserve.
&#8220;No reserve, because if you&nbsp;want decentralization to fail, you'd&nbsp;put the government in charge&nbsp;of it,&#8221; he stated as his first and the most ideal choice.
However, if reserves must be set up, Yakovenko said they should be managed by states as a &#8220;hedge&#8221; against the Federal Reserve making a mistake.
In the case of a federally administered reserve, Yakovenko proposed basing it on &#8220;objectively measurable requirements.&#8221; 
&#8220;I don't care what they are, they can even be constructed such that only Bitcoin satisfies them right now, they just must be objectively measurable and rationally justified,&#8221; he explained his point.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My reserve order of preference 1. No reserve, because if you want decentralization to fail you'd put the government in charge of it. 2. Or states run their own reserve as a hedge against the fed making a mistake 3. Or if there has to be a reserve, it's based on objectively… <a href="https://t.co/LfYXCIeRnG">https://t.co/LfYXCIeRnG</a>
&mdash; toly &#x1f1fa;&#x1f1f8; (@aeyakovenko) <a href="https://twitter.com/aeyakovenko/status/1897517764119830775?ref_src=twsrc%5Etfw">March 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
When questioned if this was an indirect confirmation that no one from Solana pitched SOL for inclusion in the recently announced U.S. cryptocurrency reserve, Yakovenko stated, &#8220;No one asked me, and I didn&#8217;t pitch it.&#8221;
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/03/44159088/microsoft-might-have-given-bitcoin-investments-a-miss-for-now-but-one-of-its-largest-investors-has-been-an-avid-advocate-of-cryptos-blockchains">Microsoft May Have Given Bitcoin Investments A Miss But A Large MSFT Stock Holder Is A Strong Crypto, Blockchain Advocate</a>
Why It Matters: Yakovenko&#8217;s comments come in the wake of the surprise announcement of a strategic reserve comprising of top coins such as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), and SOL. 
The idea of including coins other than Bitcoin has sparked criticism from certain quarters, including some of President Donald Trump&#8217;s <a href="https://www.benzinga.com/25/03/44107003/trump-faces-backlash-over-crypto-reserve-plan-from-bitcoin-supporters-including-his-own-dont-think-the-government-should-be-pumping-our-crypto-bags-with-taxpayer-money">supporters</a>. Coinbase CEO Brian Armstrong also <a href="https://in.benzinga.com/25/03/44070857/coinbase-ceo-brian-armstrong-thinks-having-a-bitcoin-only-crypto-reserve-best-option-while-arthur-hayes">stated </a>that having just Bitcoin in the reserve would be the &#8220;best option.&#8221;
That said, Commerce Secretary Howard Lutnick <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve">hinted </a>that Bitcoin might be granted a special status in the proposed reserve, while other tokens would be treated differently but positively.
All eyes will be on Friday&#8217;s <a href="https://www.benzinga.com/25/03/44064928/trump-to-host-first-ever-white-house-crypto-summit-next-friday-btc-surges-past-85000-doge-surges-over-10" target="_blank" rel="noreferrer noopener">White House crypto summit</a> to get a more comprehensive understanding of the reserve.
Price Action: At the time of writing, SOL was exchanging hands at $6.23, up 13.61% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/03/44157760/peter-schiff-predicts-a-bitcoin-strategic-reserve-will-accelerate-dollars-demise-the-ultimate-winner-will-be-gold">Peter Schiff Predicts A Bitcoin Strategic Reserve Will &#8216;Accelerate&#8217; Dollar&#8217;s Demise: &#8216;Ultimate Winner Will Be Gold&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$ETH

$SOL

$XRP

Solana Co-Founder Says A Federally Controlled Crypto Reserve Will Harm Decentralization Ethos, Proposes States Control Their Own Reserves

Offerings

HCXY

Reported Earlier, Hercules Capital Announced That It Has Agreed To Sell To The Initial Purchasers In A Private Offering, $250.0M Aggregate Principal Amount Of Its 4.75% Convertible Unsecured Notes Due 2028

Reported Earlier, Forestar Group Announced That It Has Priced An Offering Of $500M Aggregate Principal Amount Of 6.500% Senior Unsecured Notes Due 2033

Reported Earlier, Bread Financial Announced The Pricing Of Its Previously Announced Offering Of $400M In Aggregate Principal Amount Of Its 8.375% Fixed-rate Reset Subordinated Notes Due 2035

2025 guidance
<ul>
<li>South Bow has reduced its outlook for normalized EBITDA for its Marketing segment by approximately $30 million relative to 2024, due to continued impacts of WCSB crude oil pipeline capacity exceeding supply and South Bow's response to market uncertainty caused by the potential for, and continuation of, tariffs, including the unwinding of certain positions to minimize South Bow's exposure to further pricing volatility.</li>
<li>South Bow anticipates that its interest expense for 2025 will be approximately $325 million, within a range of 2%, and that the Company's current tax rate will range from 23% to 24%.</li>
<li>Distributable cash flow is expected to be approximately $535 million, within a range of 3%, which South Bow will use to fund its expected annual dividend of $416 million ($2.00/share), subject to approval and declaration by the Board, and investments required to continue advancing the Blackrod Connection Project.</li>
<li>South Bow expects that its net debt-to-normalized EBITDA ratio will increase modestly through the course of 2025 as the Company continues to invest in the Blackrod Connection Project and incur one-time costs of approximately $40 million to $50 million associated with the Spinoff. Consistent with the Company's outlook on leverage, South Bow anticipates exiting 2025 with a net debt-to-normalized EBITDA ratio of approximately 4.8 times and that the Company will begin reducing its leverage once the Blackrod Connection Project starts generating cash flow in 2026.</li>
<li>South Bow plans to invest approximately $110 million, within a range of 3%, in growth capital expenditures for the Blackrod Connection Project in 2025. The total expected capital cost of the project is estimated to be $180 million, targeted to be ready for in-service in early 2026. As of Dec. 31, 2024, South Bow has invested $62 million in the project.</li>
<li>Maintenance capital expenditures are estimated to be approximately $65 million, within a range of 3%, in 2025, as South Bow proactively completes maintenance activities while demand for uncommitted capacity is expected to be subdued, and invests in information services infrastructure. These expenditures are generally recoverable through South Bow's tolling arrangements.</li>
</ul>
South Bow's 2025 annual guidance and a review of 2024 actual results are outlined below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>$ millions, except percentages 1</td>
<td>2024 Actuals</td>
<td>2025 Guidance</td>
</tr>
<tr>
<td>Normalized EBITDA</td>
<td>1,091</td>
<td>1,010 ± 3%</td>
</tr>
<tr>
<td>Interest expense</td>
<td>388</td>
<td>325 ± 2%</td>
</tr>
<tr>
<td>Current tax rate (%)</td>
<td>23%</td>
<td>23% - 24%</td>
</tr>
<tr>
<td>Distributable cash flow</td>
<td>608</td>
<td>535 ± 3%</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Growth</td>
<td>73</td>
<td>110 ± 3%</td>
</tr>
<tr>
<td>Maintenance 2</td>
<td>61</td>
<td>65 ± 3%</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

General

SOBO

South Bow Projects 2025 Normalized EBITDA Of Approximately $1.01B, Reaffirms Its Long-term Normalized EBITDA Growth Outlook Of 2% To 3%

South Bow Reports Q4 2024 GAAP EPS Of $0.54 Vs. $0.45 YoY, Sales Of $488M Vs. $540M YoY

Skanska is investing about SEK 1 billion in the first phase of the office complex Solna Link at Solna Station in Arenastaden, Sweden. The construction contract is worth about SEK 480M, which will be included in the order bookings for Sweden for the first quarter 2025.
The first phase of the nine-storey office building will have a leasable area of approximately 16,000 square meters. The entire Solna Link, located along the tracks at Solna Station, will encompass about 36,000 square meters. In addition to office space, the ground floor will house a gym, conference rooms, lounge, restaurant, café, and bicycle service. Just a few minutes from Solna Link is Westfield Mall of Scandinavia with shops, restaurants, and all other types of services.
The project will be LEED certified with the ambition to achieve Platinum level, and it is also pre-certified according to NollCo2 and WELL Gold.
Construction work is set to begin in March 2025 and the office building is planned for completion in the first quarter of 2027.

SKBSY

Skanska Invests SEK 1B in Solna Link Office Complex, Begins Construction in March 2025

FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) and Malaysia Marine and Heavy Engineering Sdn Bhd (MMHE), a wholly owned subsidiary of Malaysia Marine and Heavy Engineering Holdings Berhad (KLSE: MHB), have announced the signing of a Joint Development Agreement (JDA) to co-develop large-scale hydrogen production systems and technologies across Asia, New Zealand, and Australia.
Building on a memorandum of understanding signed in February 2023, the JDA represents a pivotal step for the two companies, driven by a shared vision to make clean hydrogen production easily accessible and viable. The collaboration underscores FuelCell Energy and MHB's commitment to advancing green energy solutions and supporting global decarbonization and energy transition goals.
Under the terms of the JDA, the two companies will bring together FuelCell Energy's cutting-edge solid oxide electrolyzer (SOEC) technology and MHB's expertise in large-scale fabrication to develop modular solutions that support rapid deployment of commercial hydrogen production.
&nbsp;
Project Award: Detailed Feasibility Study (DFS) in Malaysia
In conjunction with the JDA, FuelCell Energy and MHB are collaborating to support a contract awarded to FuelCell Energy for a Detailed Feasibility Study (DFS) of a low-carbon fuel production facility in Malaysia. The DFS will evaluate the production of low-carbon fuel utilizing SOEC technology with carbon dioxide and water as feedstocks.
Additionally, as part of the DFS, the companies will collaborate with KBR LLC, which will provide its proprietary low-carbon fuel synthesis technology.
The project aligns with Malaysia's goals to achieve net-zero carbon emissions by 2050, while advancing its national hydrogen value chain.

Government

Regulations

FCEL

FuelCell Energy and MMHE Partner to Expand Large-Scale Hydrogen Production Across Asia and Australia

<a href="https://www.globenewswire.com/Tracker?data=Dpe5uBgPoRsuPOQGNwzt4IJT8XrmnvAhEssnuY-JhnmjOqVNg5B_2V5q6UvyAibulWUWNNzAel2mN0rHqhDuf2fXQH5XE_U9Ip7xRBSiIJXrWHbwT4w36NknfmZNGyHvwZOXeOOkooujjKGCo7RmbdGzPhWqs6Z3r90s46OfUSWwZuvusTfI2_r1ngsCYd0DcOzdzRQTr8QC1RBQB3kj2A==">Lantronix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>), a global leader of compute and connectivity for IoT solutions enabling Edge Intelligence, today announced that it will demonstrate its <a href="https://www.globenewswire.com/Tracker?data=qeH--YO6r-k5_EVN380NHF0E5AB0mzXlq7_2JguTbH2G9CCDuzbp5kfZ23_KKM1UDFHDhhVHuR-TB_l6KcWXB6qIDb0XFzxwttSUUiu7pQkm9Nyt_OCOV4suehN8ZKvurjC4ddEF80ur8n2IHtPdN-eRqn2futGUAXNLFMNB3-iCgk7O7b3dkldbX117gl41RQCreJ82ZmC-wVQSZUetTw==">SmartLV,</a> the first AI-enabled IoT Edge Compute Cellular Gateway, in the Qualcomm&#xAE; Technologies Booth at Hall 5/5-161 at Embedded World, March 11–13, 2025, in Nuremberg, Germany. Powered by the Qualcomm Dragonwing&#x2122; IQ-615, this groundbreaking innovation is designed specifically for low-voltage substations and distribution automation applications in next-generation smart grids, utilities and industrial sectors.
The Lantronix SmartLV demonstration in Qualcomm Technologies' booth at Embedded World will highlight the cutting-edge Edge AI capabilities of this next-generation IoT cellular gateway, which utilizes the Dragonwing IQ-615. The SmartLV demo will showcase real-world use cases, including real-time monitoring of power consumption for a low-voltage grid. Combining this data with real-world pricing information enables grid operators to steer power and users to cost-optimize their consumption.

LTRX

Lantronix To Unveil AI-Powered SmartLV IoT Gateway for Smart Grids at Embedded World 2025

AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) ("AlTi" or "AlTi Tiedemann Global"), a leading independent global wealth manager with over $77 billion in combined assets, announces the acquisition of Kontora Family Office GmbH ("Kontora"). Kontora is a multi-family office and asset management company headquartered in Hamburg, Germany focused on UHNW families, entrepreneurs and select institutions. The firm has assets under management ("AUM") of approximately Є14 billion.
The acquisition further advances AlTi's growth strategy to become the leading global independent wealth management platform for the UHNW, with targeted expertise in alternatives. This landmark transaction is the first European-based acquisition AlTi has executed following the strategic investment from Allianz X and Constellation Wealth Capital, having completed two US-based acquisitions in 2024. A portion of the funding from Allianz X was earmarked for AlTi's expansion into Germany, reflecting the opportunity within the German wealth management market.
Kontora is a founder-run business with a close-to 20-year track record, offering a range of services including family office, investment office, and service office solutions, tailored to preserve and grow client wealth across generations. Kontora, which primarily serves clients in Germany and Austria, specializes in open and closed-end funds and alternative strategies, with a service office focused on the administration and structuring of financial assets for large family offices, foundations, and non-profits. As part of the transaction, it is expected that Co-Chief Executive Officers Stephan Buchwald and Dr. Patrick Maurenbrecher will reinvest a portion of the proceeds into AlTi and will undertake senior positions within AlTi to play a key role in the execution of AlTi's strategy for the German market.

ALTI

AlTi Global Expands into Germany with Acquisition of Kontora, Adding €14B in AUM

David Kostin, the Chief U.S. Equity Strategist of Goldman Sachs, has revised his earnings growth forecast, citing a weaker economic outlook, and highlighted a shift in market trends.
What Happened: On CNBC&#8217;s &#8216;Squawk on the Street&#8217;, Kostin discussed his revised earnings growth forecast and market trends. Initially projected at 11%, the earnings growth forecast for 2025 has now been adjusted to 9%. 
Despite this, Kostin maintains that the earnings growth for 2026 remains at 7%, unchanged. He also stated that the S&amp;P 500 year-end target remains at 6500, suggesting an 11% gain from current levels.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Goldman Sachs&#039; Kostin: We&#039;re revising EPS growth forecast lower, but healthcare poses opportunity" width="500" height="281" src="https://www.youtube.com/embed/Pn9ySR9ygao?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Kostin also noted a shift in investment strategy, with investors moving from &#8220;excitement&#8221; (cyclicals) to &#8220;boredom&#8221;&nbsp;(defensive stocks) amid tariff&nbsp;uncertainties. He identified healthcare and consumer staples as preferred sectors for their stability and less sensitivity to the ongoing trade war. He also named&nbsp;Thermo Fisher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) and Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) as strong investment options. 
Furthermore, he notes a shift in focus from AI infrastructure and hyperscalers to software companies that would be leveraging AI to amplify their revenues, for instance, MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>). 
According to Kostin, uncertainty around tariffs makes forecasting difficult, but models suggest&nbsp;earnings will be impacted through unit volumes and margins. The strategist estimated that a 5% increase in tariffs&nbsp;could reduce earnings growth by&nbsp;1-2%.
SEE ALSO: <a href="https://www.benzinga.com/general/space/25/03/44102170/spacex-scraps-starship-flight-test-on-monday-too-many-question-marks-about-this-flight-says-ceo-elon-musk">SpaceX Scraps Starship Flight Test On Monday: &#8216;Too Many Question Marks About This Flight&#8230;,&#8217; Says CEO Elon Musk</a>
Why It Matters: This shift in investment strategy is noteworthy, considering that institutional investors were bullish on technology and financials during the fourth quarter of 2024. Investors were seen <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">pulling back</a> from the healthcare sector, which Kostin now identifies as a preferred sector. Even Warren Buffet&#8216;s Berkshire Hathaway trimmed its stake in healthcare provider DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), bringing down the ownership to 45%.
These market shifts and Kostin&#8217;s revised forecast underline the uncertainties in the current economic climate but also highlight potential&nbsp;opportunities in defensive sectors and&nbsp;AI-driven businesses. That being said, Kostin expects the falling bond yields to offset some tariff effects, potentially benefiting the economy. He summed up by saying that GDP growth is the primary driver of earnings, with interest rates and inflation playing secondary roles.
The S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) climbed 1.12% to close at 5,842.63 on Wednesday after President Donald Trump pushed back auto tariffs on Canada and Mexico by one month.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44159766/us-indicts-12-chinese-nationals-over-alleged-global-hacking-operation-targeting-critics-been-paying-hackers-for-hire-to-inflict-digital-harm-on-americans">US Indicts 12 Chinese Nationals Over Alleged Global Hacking Operation Targeting Critics: &#8216;&#8230;Been Paying Hackers-For-Hire To Inflict Digital Harm On Americans&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Goldman Sachs Cuts Earnings Growth Outlook, Sees Investors Move From 'Excitement' To 'Boredom'

RVLV

Revolve Group And Muus Collective, Inc. Announced The Worldwide Launch Of BELLEMINT, The Cutting-edge Fashion Styling Game That Seamlessly Merges Interactive Play With Real-world Shopping

Reported Earlier, Lockheed Martin's LM 400 Tech Demo To Prove Out Design And Risk Reduction Efforts On Orbit Ready To Launch No Earlier Than March 15

Reported Earlier, Dupont Will Showcase Its Cutting-edge Advancements In Circuit Materials At Intelligent Asia Thailand 2025

Reported Earlier, Lithium Americas Announced A Strategic Investment Of $250M From Fund Entities Managed By Orion Resource Partners LP

Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.18 by 33.33 percent. This is a 71.43 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $302.20 million which beat the analyst consensus estimate of $262.78 million by 15.00 percent. This is a 13.90 percent increase over sales of $265.31 million the same period last year.

Earnings Beats

Earnings Misses

Reported Earlier,Fortuna Silver Mines Q4 2024 Adj EPS $0.12 Misses $0.18 Estimate, Sales $302.20M Beat $262.78M Estimate

CFLT

Confluent Announced Sccc By Stc—A Leading Cloud Services Provider In Saudi Arabia—Has Joined The Confluent OEM Program As A Managed Service Provider (MSP) To Make Data Streaming More Accessible In Saudi Arabia

ALGM

Reported Earlier, Onsemi Submitted Proposal To The Board Of Directors Of Allegro Microsystem To Acquire The Company For $35.10 Per Share In Cash At An Implied Enterprise Value Of $6.9B

Reported Earlier, The Allegro Board Of Directors Reviewed The Unsolicited Acquisition Proposal From Onsemi For $35.10 Per Share, In Consultation With Its Independent Financial And Legal Advisors, And Determined That The Proposal Was Inadequate

QGEN

QIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States

Press Releases

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Management

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Arvinas

BGM Group

Belite Bio, Inc - American Depositary Shares

Belite Bio

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GH Research

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Innoviva

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Citizens Capital Markets

Stifel

HC Wainwright & Co.

JMP Securities

Cantor Fitzgerald

스트럭처 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다.
What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#8220;비중확대(Overweight)&#8221; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.
스트럭처 테라퓨틱스는 GLP-1 체중 감량 시장을 겨냥해 고안된 경구용 알약인 &#8216;1290&#8217;이라는 약물 후보를 개발하고 있다. 이 약물은 잠재적으로 경쟁사보다 1~2년 앞서 시장에 출시될 수 있는 소분자 제제를 기반으로 한다.
이 약은 다른 경구용 체중 감량 약물 후보와 차별화되어 안전성에 큰 우려가 없는 환자에게 상당한 체중 감량 효과를 제공할 것으로 기대된다.
"우리는 전례 없이 큰 시장에서 구강 시장에서 GPCR의 시장 점유율이 시간이 지남에 따라 5%에 접근할 수 있다고 생각한다. 전체적으로 우리는 1290/스트럭처가 T2D/비만 시장에 참여하려는 대규모 바이오제약 회사들에게 매력적인 파트너십 기회가 될 수 있다고 생각한다"라고 JP모건이 말했다.
JP모건은 스트럭처 테라퓨틱스의 경구용 GLP-1 체중 감량 약물 후보가 2035년까지 10억 달러 이상의 최고 매출을 올릴 수 있을 것으로 믿고 있다. 이 회사는 2023년 2월에 상장되었다.
참조: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38910906/bitcoin-dogecoin-ethereum-retrace-on-profit-taking-by-retail-investors-analyst-predicts-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 도지코인, 이더리움은 소매 투자자들의 이익 실현에 하락</a>
Why It Matters: 비만 치료제 시장은 중요한 발전을 보이고 있다. 최근 로슈(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)은 이중 GLP-1/GIP 수용체 작용제 CT-388의 1b상 시험에서 유망한 결과를 발표하여 비만 치료 시장에서 <a href="https://www.benzinga.com/general/biotech/24/05/38878582/roche-to-ride-booming-obesity-treatment-market-with-newly-acquired-drug-candidate">상당한 잠재력</a>을 나타냈다.
또한 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 중국에서 당뇨병 치료제 티르제파티드(tirzepatide)에 대한 승인을 확보하여 중요한 아시아 시장에서 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와의 <a href="https://www.benzinga.com/general/biotech/24/05/38941485/eli-lilly-secures-china-nod-for-popular-weight-lossdiabetes-drug-tirzepatide">경쟁</a>이 치열해질 수 있는 발판을 마련했다.
앞서 바이오헤븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)은 체중 감량을 돕는 동시에 근육 손실을 예방할 수 있는 실험 약물인 탈데프그로벱 알파(taldefgrobep alfa)(BHVN-2000)를 통해 비만 치료제 시장에 대한 <a href="https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff">다른</a> 접근 방식을 강조했다.
다음 읽기: <a href="https://www.benzinga.com/tech/24/05/38919616/apples-groundbreaking-iphone-16-could-spark-another-stock-surge-building-on-an-800-growth-over-the-l?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, 6월 WWDC에서 아이폰 13 시리즈 공개 예고</a>
AI를 통해 생산된 이미지
<hr class="wp-block-separator has-alpha-channel-opacity" />
Benzinga Neuro의 기술, <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a> 편집
<hr class="wp-block-separator has-alpha-channel-opacity" />
GPT-4 기반의 Benzinga Neuro 콘텐츠 생성 시스템은 광벤짜 생태계의 네이티브 데이터, API 등을 활용하여 포괄적이고 시의적절한 이야기를 제공합니다. <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">더 알아보기</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />

Comments

Structure Therapeutics

뉴스

에 대한 최신 뉴스 Structure Therapeutics (NASDAQ:GPCR) 주식

수요일, 5월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌